REPLIGEN CORP acquires FlexBiosys, Inc.
The deal at a glance
REPLIGEN CORP acquired FlexBiosys, Inc. for ~$41.0 million total ($29.0M cash + Repligen stock, plus earnouts), a transaction completed in April 2023, structured as combination (cash plus stock) with earnouts.
FlexBiosys, Inc. operates in Fluid Management, is based in Branchburg, New Jersey, USA. Acquisition of all outstanding equity interests in FlexBiosys, Inc., a custom designer and manufacturer of single-use bioprocessing products, strengthening Repligen's fluid-management portfolio. Earnout periods run from Jan 1, 2023 through Dec 31, 2024.
Per Repligen's 10-K, FlexBiosys offers expert design of custom single-use bioprocessing products, strengthening the fluid-management portfolio.
Custom single-use product design capability. Strengthens fluid-management portfolio. Repligen Fluid Management
No advisory firms have been disclosed for this transaction.